🔴 Summit Therapeutics is trading 4.4% down; no clear company-specific catalyst identified

Summit Therapeutics is trading at $15.66, down 4.40%, with no clear company-specific catalyst identified for the September 25 decline.

• The company’s latest listed press release was dated September 22 and concerned a Phase III trial presentation at ESMO 2026, not a same-day announcement.
• Major indices were modestly higher in the supplied market context, so the decline does not appear to track the broader market’s direction. Available evidence does not establish a specific cause.